Anti-frizzled antibodies and methods of use
The present invention provides anti-Fzd monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of diseases.
1. An isolated antibody, or an antigen-binding fragment thereof, that binds to Frizzled 5 and Frizzled 8, comprising:
a heavy chain variable region comprising CDRH1, CDRH2 and CDRH3 sequences set forth as SEQ ID NOs: 218, 410, and 861, respectively; and
a light chain variable region comprising CDRL1, CDRL2 and CDRL3 sequences set forth as SEQ ID NOs: 996, 1071, and 1264, respectively.
2. The isolated antibody, or antigen-binding fragment thereof, of claim 1 , comprising a heavy chain variable region comprising an amino acid sequence having at least 90% identity to the amino acid sequence set forth in SEQ ID NO:7 and a light chain variable region comprising an amino acid sequence having at least 90% identity to the amino acid sequence set forth in SEQ ID NO:44.
3. The isolated antibody, or antigen-binding fragment thereof, of claim 1 , wherein the antibody, or antigen-binding fragment thereof, is humanized.
4. The isolated antibody, or antigen-binding fragment thereof, of claim 1 , wherein the antibody, or antigen-binding fragment thereof, is an IgG antibody, a single chain antibody, a scFv, a univalent antibody lacking a hinge region, a Fab or a Fab′ fragment, or a minibody.
5. A pharmaceutical composition comprising a physiologically acceptable excipient, diluent, or carrier, and the isolated antibody, or antigen-binding fragment thereof, according to claim 1 .
6. The isolated antibody, or antigen-binding fragment thereof, of claim 1 , comprising a heavy chain variable region comprising an amino acid sequence having at least 95% identity to the amino acid sequence set forth in SEQ ID NO:7 and a light chain variable region comprising an amino acid sequence having at least 95% identity to the amino acid sequence set forth in SEQ ID NO:44.
7. The isolated antibody, or antigen-binding fragment thereof, of claim 1 , comprising a heavy chain variable region comprising an amino acid sequence having at least 98% identity to the amino acid sequence set forth in SEQ ID NO:7 and a light chain variable region comprising an amino acid sequence having at least 98% identity to the amino acid sequence set forth in SEQ ID NO:44.
8. A pharmaceutical composition comprising a physiologically acceptable excipient, diluent, or carrier, and the isolated antibody, or antigen-binding fragment thereof, according to claim 7 .